



Supplementary Figure S1 BDG = 1,3-Beta-D-glucan; BSW = biomedical support worker; BMS = biomedical scientist; MRL = United Kingdom Health Security Agency (UKHSA) Mycology Reference Laboratory; OM = outcome metric; PM = process metric; IM = input metric (potential confound shown with dotted line)



Supplementary Figure S2 Durations of stages of the BDG testing pathway showing mean for each stage and aggregate TAT target for comparison. The sample is April 2021 (n=70 test requests after 1 extreme outlier removed), when the mean aggregate TAT was 10.1 days.



Supplementary Figure S3 Pareto chart of the median duration in days for the stages of the pathway.
The sample is April 2021 (n=70 test requests after 1 extreme outlier removed), when the mean aggregate TAT was 10.1 days (median 9.5 days).